CLINICAL EVALUATION OF S-1108 IN CHILDREN

Abstract

We administered S-1108 to 16 children with ages ranging from 7 month to 15 years at doses between 1.8 and 6.0mg/kg×3/day for 3 to 13 days. We evaluated the efficacy and safety of S-1108 in 11 children with respiratory tract infections, 3 urinary tract infections, and 2 skin infections. The efficacy rate of S-1108 was 100% and bacteriological eradication rate was 83.3%. No adverse effects were observed. These results suggested that S-1108 could be used safely in children.